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INTRODUCTION
The rodent models
In the previous papers presented in this issue, the descriptions of various forms of transmissible spongiform encephalopathy (TSE) have illustrated how they form a group of unique diseases which are invariably fatal and which are characterised by an extended but predictable incubation period and spongiform degeneration of neuronal tissue. Unlike other infectious diseases, the TSEs are not accompanied by a detectable immune or inflammatory response. The brains of affected animals accumulate an aggregated amyloid protein which may be organised into characteristic plaques. Although infectious, TSEs are not highly contagious in the sense that many viral diseases are, but for sheep and goats they can be naturally transmitted by infected dams to their offspring or from infected to uninfected members of a flock by means not yet understood. Significant outbreaks of TSE in other animal species most probably represent "unnatural" exposure to significant levels of the transmissible agent through the consumption of infected feed.
This volume is concerned primarily with the TSEs of animals but analogous diseases in man are providing important molecular genetic information and it is appropriate to briefly consider these. There are three recognisable but rare human diseases: Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker (GSS) syndrome and kuru. The properties of these are summarised by Hsiao and Prusiner (58) . Of the three, CJD is the most common, having an annual incidence of about one in a million of the population, and presenting in spontaneous, familial and iatrogenic forms. GSS is approximately tenfold less common than CJD and wholly familial in incidence. Although apparently inherited, examples of GSS and familial CJD have been transmitted to experimental animals. Kuru was restricted to, but common amongst, the Fore people of Papua New Guinea, transmission probably being linked to cannibalistic ritual burial practices. Extensive epidemiological studies have so far given no clue as to the source of any putative infectious agent in cases of sporadic CJD, as the overall incidence is found to be similar around the world and, although there are local pockets of high incidence of familial disease, there is no association between CJD incidence and particular human groupings or activities. There is also no association between CJD and the presence of sheep, goats or the occurrence of scrapie infections in flocks. When considering the animal TSEs, characterised by their high incidence or significant outbreaks, it is worth bearing in mind that an equivalent incidence of disease to that present in the human population would almost certainly have gone unrecognised in an animal population. Thus other TSEs may be present naturally in wild and domesticated animal species, but at such low levels as to have been missed.
The ability to transmit scrapie by direct transfer of infected material from an affected animal to an unaffected animal ultimately led to the development of experimental models in the mouse and hamster (26) . Much of what is now known of the molecular details of these diseases comes from these two rodent systems. Most importantly, the ability to transmit disease to a mouse (or hamster) has provided the only workable bioassay for infectivity, thus enabling protocols for the purification of the infectious agent to be monitored in terms of the partitioning of infectivity. The assays are extremely cumbersome, time-consuming and insensitive and it remains the case today that there is no assay for the agent itself, only its infectivity.
Nevertheless, use of these model rodent systems has provided, directly or indirectly, important insights into various molecular aspects of the diseases. Most importantly it has been possible to: a) identify and characterise different isolates and strains of infectious agent; b) define the host genes which influence incubation and pathology of disease; c) produce sufficient quantities of experimentally controlled, highly infectious tissue to undertake biochemical fractionations; and d) enable the purification and characterisation of the host-encoded protein, PrP, which plays a central role in disease pathogenesis as well as being an important component in the agent itself.
The elements of strain type, host genes and PrP protein are inextricably interlinked, and it is not useful to discuss one without the others.
The existence of different strains -biological evidence for "genetic" variation in the agent
The ability to transmit scrapie from sheep or goats to mice enabled Dickinson and co-workers (34) to identify several different strains of scrapie agent. These are differentiated largely on the basis of the relative time periods from inoculation to the appearance of clinical disease in defined strains of mice differing at the Sinc gene locus (see the section entitled "Host genes which influence the course of the disease") (34, 35) and a semi-quantitative graphic measure of histopathology termed the "lesion profile" (46) . Such criteria can be envisaged as the end result of complex biological processes involving agent-host cell receptor interactions, agent replication, agent transport and agent-induced molecular pathology, aspects of which must be influenced by the information carried by the agent itself. Some strains retain their distinguishing characteristics through multiple passages in mice of different genetic background indicating that the informational identity of the agent can be independent of the host (13) . Strains can be sufficiently stable to maintain their individual properties when passaged as mixtures in mice (36) and when passaged between different host species (66) . Conversely, other strains are less stable and appear to undergo changes analogous to mutation, often in a predictable way, upon passage through hosts of defined and constant genetic background (13) . While much of the work characterising different strains of scrapie has been with well-established strains with long passage histories, similar stable strain variation has been described for ten recent isolates from five scrapie-positive sheep (20) .
The existence of numerous distinct strains of scrapie agent is indicative of some form of agent-specific informational molecule. In conventional molecular terms this would be envisaged as being a nucleic acid, either single-or double-stranded DNA or RNA, but other options have been proposed, most notably the PrP protein itself (see the chapter entitled "The molecular nature of the transmissible agent").
Host genes which influence the course of disease
About twenty-five years ago Dickinson and co-workers (34) identified a single autosomal gene which controlled the incubation period for some strains of scrapie in mice. This gene, termed Sinc for Scrapie incubation period, has two alleles designated s7 and p7 for short and prolonged incubation periods, respectively, following challenge with the ME7 strain of scrapie. An analogous incubation period gene, designated Prn-i, has been described by Carlson et al. (18) with equivalent "short" (Prn-i a ) and "long" (Prn-i b ) incubation period alleles. Thus the classification of a murine scrapie strain depends on the relative incubation periods of Sinc s7/s7 homozygous, Sinc p7/p7 homozygous and Sinc s7/p7 heterozygous Fl mice and details of the lesion profiles. The recipient mice are often C57B1 and VM strains and Fl progeny of the C57B1 x VM cross, but the development of Sinc congenie mouse lines has enabled the genetic contribution of the Sinc gene to disease processes to be more precisely defined (16) . Most murine-adapted scrapie strains, like ME7, have shorter incubation periods in Sinc s7/s7 homozygotes and prolonged incubation times in Sinc p7/p7 homozygotes, but strains which reverse this "phenotype" have been discovered. In Sinc s7/p7 heterozygotes individual scrapie strains may exhibit either an intermediate incubation period phenotype or one which is longer than both of the homozygotes (16) .
Unlike mice, hamsters do not have a similar host incubation period gene allelism, and, hence, are not as useful for strain typing and classical genetic analysis. However, the 263K scrapie strain in the hamster remains the shortest incubation period scrapie model to date and yields the highest titre of agent in brain tissue (65) . This has made the hamster model of major use in the biochemistry and molecular biology of the disease and the causative agent.
The development of scrapie disease in sheep also depends principally on a single gene called Sip, which is the functional homologue of the murine Sinc gene, and which has two alleles sA and pA (37) . Unravelling the genetics of scrapie susceptibility was more complicated in the sheep than for mice, not least because genetically inbred lines of sheep do not exist. Nevertheless, a flock of Cheviot sheep was selected on the basis of the response of the animals to challenge with the mixed sheep scrapie brain pool, SSBP-1. Sheep developing disease within 300 days of inoculation were bred as the "positive" line and those which did not show clinical signs of disease within their normal lifetime were grouped in the "negative" line. Sheep in the "negative" line are Sip pA/pA homozygotes whilst those in the "positive" line are Sip sA/sA homozygotes or Sip sA/pA heterozygotes (33) . Just as with the mouse, the Sip sA allele of a Cheviot sheep is partially dominant when using the SSBP-1 agent mixture (45) , but the behaviour of Sip short (sA) and prolonged (pA) incubation period alleles can only be defined in terms of the infecting strain of scrapie agent and the recipient breed of sheep. The CH1641 strain, for example, will reverse the incubation period phenotype of the Sip alleles, with Sip pA/pA homozygous sheep succumbing to disease after a short incubation period (44) .
The existence of apparent autosomally dominant genes which determine predisposition to CJD and GSS in man suggests that these may represent the human equivalent of the murine Sinc and ovine Sip genes. A formal genetic experiment to test this is, of course, not possible, but the existence of extended family pedigrees and well documented clinical records over several generations has provided excellent material in which to study the molecular genetics of the human TSEs (see the section entitled "Mutations in the human PrP gene associated with TSEs").
THE HOST-ENCODED PROTEIN -PrP
Purification of infectivity and the isolation of PrP
Faced with the question of the nature of the scrapie infectious agent, molecular scientists have responded by attempting to fractionate biochemically scrapie-infected tissue to establish with which molecular fractions the infectivity co-purified. Initial studies indicated that infectivity co-purified with membrane fractions (85) , but following the introduction of different detergents to solubilise membrane fractions (86) and the use of differential centrifugation and nucleolytic and proteolytic digestion steps (39, 71, 83, 91) it became clear that the major component of highly purified infectious fractions was a hydrophobic protein. Partial sequencing of this protein enabled the cloning of the nucleic acid which encoded it and the, then, surprising observation that this apparently infection-associated protein was encoded by a host gene (87) . One biochemical feature which proved critical in the purification of the protein was its relative resistance to proteolysis by proteinase K (78) , which provides one derivation of its name, PrP (proteinase-resistant protein). Subsequent experiments using antisera to this protein have shown that PrP is present in extracts of many normal tissues as well as those of diseased tissues (56) , the relative resistance to proteinase digestion being acquired by the structural changes which accompany the disease. Normal cellular PrP is referred to as PrP c whereas the proteinase-resistant scrapiespecific form is called PrP Sc . Aggregated PrP Sc is equivalent to the scrapie-associated fibrils (SAF) found in detergent and proteinase K-treated brain extracts of TSEaffected animals (83) and which may be assembled in vivo (110) .
The same reagents used to characterise PrP immunochemically have been used to identify accumulations of PrP in amyloid plaques and degenerating neuronal tissue of histological preparations of TSE affected brains (14) . A later section discusses the question of whether PrP is itself an infectious agent, or whether in combination with other, as yet undefined, molecules it forms an infectious particle (see the chapter entitled "The molecular nature of the transmissible agent"). It is clear, however, that PrP plays a pivotal role in the molecular pathogenesis of the TSEs. The structure of PrP will be considered in more detail.
Structure of PrP
It is the Syrian golden hamster PrP which has so far yielded the most structural data and, since both alleles in the hamster yield the same polypeptide, it is also the simplest model. For these reasons the following description of PrP is based principally upon this model. The primary amino acid structures of the PrPs of five rodent species have been derived from cDNA (75, 87) and genomic (118) cloning and sequencing experiments and are shown in Figure 1 . Nascent hamster PrP consists of 254 amino acid residues, of which the N-terminal 22 amino acid residues constitute a signal sequence which directs the translocation of the protein into the lumen of the endoplasmic reticulum where it is then cleaved off (4, 57, 116) . Removal of the signal peptide leaves the protein with a highly basic N-terminus.
Much of the N-terminal third of PrP is dominated by repeated amino acid motifs (Fig. la) . A pair of hexapeptide repeats lies immediately adjacent to a contiguous series of five octapeptide repeats. Conformation-predictive analysis suggests that the octapeptide repeats should form a stack of ß-turn segments (5).
Almost centrally in the polypeptide chain there is a contiguous stretch of 20 hydrophobic amino acid residues (Figs, la and lb). Indeed it meets the criteria of a stop-transfer effector (STE), which would position these amino acid residues as a membrane-spanning zone that could project the amino-terminal region of PrP back into the cytosol. At this point however, the experimental data from two different in vitro protein translation systems conflict with the predictions; although STE functionality was observed in the course of translating PrP mRNA in the wheat-germ cell-free system, the same mRNA translated in a rabbit reticulocyte lysate system led to complete translocation of the polypeptide into the microsomal lumen (122) . Incorporating the coding region for this putative STE of PrP into non-PrP chimaeric messenger RNAs has subsequently demonstrated that this is a repeatable phenomenon and that the difference is attributable to its unique structure and possible interaction with cytosolic factors (76, 122) . Whether or not this hydrophobic region has any bearing on PrP biosynthesis or topology in vivo still remains to be determined.
There are two regions which are predicted to tend towards amphipathic α-helix, spanning amino acid residues 137-175 and 195-217 in hamster PrP (5) . Correct helical coiling would present, for both regions, a relatively hydrophobic "stripe" capable of hydrodynamic interaction with membrane or other hydrophobic domains.
Two cysteine residues (179 and 214) complex to form a disulphide bridge, residue 214 being within the second potential-helical domain (116) . The 34 amino acid residue loop which this forms has two potential sites for the addition of N-linked oligosaccharides (asparagine residues 181 and 197). The original deduction that PrP is a sialoglycoprotein was made on the basis of its behaviour in chromatographic systems following glycosidase treatment (which removes sugars) and by the ability of its carbohydrate side chains to bind various lectins. As much as 35% of the relative molecular weight (M r ) of the mature PrP might derive from carbohydrate. That both potential N-linked glycosylation sites are in fact modified with oligosaccharides has been demonstrated by careful and extensive analysis of oligosaccharides released from PrP Sc by enzymatic and chemical treatments.
Nine different varieties of oligosaccharide were detected which contained variously branched cores of between 9 and 17 sugar residues, comprising N-acetylglucosamine, fucose, mannose and galactose, and of which more than 70% were terminally sialylated with up to 3 sialic acid residues per oligosaccharide (42, 54) . Such is the diversity of these N-glycans that Endo et al. (42) have calculated that 401 different isoforms of PrP Sc can exist when both asparagine residues are glycosylated. Some of this sugar-related complexity is clearly in evidence when PrP is subjected to two dimensional gel electrophoresis, using, in the first dimension, non equilibrium pH gel electrophoresis and, in the second dimension, sodium dodecyl sulphate Polyacrylamide gel electrophoresis (2D-NEPHGE/SDS-PAGE) followed by detection of proteins by Western-blotting and carbohydrate moieties by lectin-blotting (111) . Conducting the same level of analyses on PrP c has not been feasible owing to the relatively small amounts of protein extractable from uninfected brain. However, enzymatic digestion and lectin binding analyses indicate the presence of similar amounts and varieties of constituent sugars (103) .
There is an additional glycan moiety attached to the C-terminus of PrP, which forms an integral part of the glycophosphatidylinositol (GPI) anchor (3, 112) . The post-translational attachment of the GPI anchor occurs concomitantly with the removal of 23 amino acid residues from the C-terminus. GPI anchor structures have so far been found on, and characterised for, only a small number of proteins and these are all exclusively associated with the external face of eukaryotic plasma membranes. The GPI anchor of hamster PrP Sc is broadly similar to all others so far studied, with the α-carboxyl group of serine residue 231 being covalently attached through phosphoethanolamine to a short-chain, branched glycan, which is attached via the myo-inositol head group to a molecule of phosphatidylinositol (PI). In all cases the two fatty acyl chains of PI are embedded in the external leaflet of the plasma Searching the databases of both nucleic acid and protein sequences has drawn only one significant match at the protein level. This is to a chicken protein called 65-21, potentially with a designated function (55) . Protein 65-21 was initially fractionated from chick neuromuscular membrane fractions during purification of the acetylcholine receptor inducing activity (ARIA), to a point where N-terminal sequence information enabled anti-peptide antiserum to be raised and used to isolate cDNA clones. The complete 65-21 protein structure has 34% similarity to hamster PrP but certain key features are remarkably similar and more highly conserved. It bears eight copies of a hexapeptide repeat comparable to PrP's octapeptides, a nearly identical 20 amino acid hydrophobic domain and 2 cysteines, all of which correspond topologically between the two proteins. It is GPI anchored and has four potential N-linked glycosylation sites. Whether or not 65-21 actually has ARIA activity itself remains to be determined; early experiments have proved negative. Likewise, further analysis is required to determine whether this is in fact chicken PrP or a closely related protein.
These then, are the salient features of the best characterised PrP molecule, and are a composite of derived nucleic acid-to-protein sequence data, biochemical analysis of both PrP c and PrP
Sc , and the most reliable of the many computer-based, structure-predictive, programmes. While this is of great merit, still more important will be the three-dimensional structural information that stems from X-ray crystallography. Owing to the paucity of PrP, even in the brains of terminally ill animals, it seems most likely that the relatively large amounts of PrP required for such experiments will have to be obtained through genetic engineering, work which is already under way. Based on present knowledge, what are the structural differences which confer the characteristic physico-chemical properties of the cellular and scrapie isoforms of PrP ?
Differences between PrP c and PrP
Sc
During the course of the disease, certain changes in the physical properties of PrP become evident. Clearly the most striking are its propensity to form oligomeric structures, not seen at all with PrP c , and its acquisition of partial proteinaseresistance. It is possible that it is the sequestration of PrP in oligomeric forms alone which prevents access to proteinases by steric hindrance. Amyloid plaques, which are one of the characteristic brain lesions of some of the animal and human diseases, stain immunochemically for PrP (14) demonstrating a capacity for PrP oligomerisation in vivo. That PrP Sc oligomerises into fibrils which are resistant to dispersion in high concentrations of detergents such as 10% N-lauroylsarcosine while PrP c is fully solubilised, has been the core feature of PrP Sc (and infectivity) purification schedules for a decade. Whether this is a purification of pre-existing fibrils (e.g. amyloid) or a feature of detergent extraction is still not entirely clear.
Strongly denaturing conditions e.g. 90% formic acid, 1 M sodium hydroxide or 4 M guanidine salts convert the fibrillar PrP Sc to a monomeric form, concomitant with loss of infectivity and with loss of the proteinase resistance. Intriguingly though, fibrillar PrP Sc appears to be completely soluble in sodium deoxycholate and phosphatidylcholine-derived detergent/lipid/protein complexes (DLPC) (47) . Liposomes resulting from dialysis of DLPC are small enough to contain only two to four molecules of monomeric PrP Sc yet retain the full infectious titre. Chloroform/methanol extraction of PrP Sc liposomes to remove the lipid results in the re-appearance of fibrillar PrP. DLPC have proved to be a useful vehicle for the immuno-affinity purification and immunoassay of PrP Sc (48) . A further, but related, difference is the differential solubility of microsomal PrP Sc and PrP c in the detergent Triton X-l14. Highly purified PrPC and PrPSc exhibit differential solubility (40) and this is convincing evidence for PrP Sc having a covalent modification not found in PrPC.
When purified as its proteinase K-resistant form, PrP Sc migrates in SDSpolyacrylamide gels with a relative molecular weight of between 27 and 30 kDa, hence its designation PrP 27-30. The sensitivity of PrP c to proteinase K means that this isoform is not found in equivalent fractions purified from unaffected brains (8) , but when PrP is extracted from both normal or infected brains by methods which avoid proteolysis, PrP migrates with a M r of between 33 and 35 kDa, being designated PrP 33-35 (56, 116) . The PrP 27-30 form of PrPSc is derived from full length PrP 33-35 by loss of an NH2 terminal domain containing the octapeptide repeats (87) (Fig. 1) . Infectivity co-purifies with PrP 27-30 indicating that the octapeptide domain has no direct involvement in transmitting infectivity.
Biosynthesis of PrP
The various steps in the biosynthesis of PrP Both the N2a and HaB lines are continuously dividing cells. Incubation with either scrapie-brain homogenate or with fibrils purified from scrapie brain at a high multiplicity of infection (moi) (e.g. 100 LD 50 per cell) generates persistently infected cultures which are stable over many serial passages. Scrapie infection does not affect their rate of growth and consequently it has been possible to sub-clone infectious lines and these are proving to be valuable experimental systems. PC 12 cells have not yet been successfully infected in their dividing form but only following differentiation in response to nerve growth factor (NGF), when they become quite highly differentiated and closely resemble peripheral neurones. NGF causes a cessation of cell division, the elaboration of long and extensive neurites and biochemical changes including neurotransmitter synthesis, and perhaps most notably, the upregulation of PrP mRNA synthesis (120) . When fully differentiated, PC12 cultures can be infected at a low multiplicity of infection (moi) (1 LD 50 per cell) of scrapie agent, and a degree of agent replication demonstrated. Removal of NGF from the cell culture medium,
FIG. 2 Schematic representation of the biosynthesis of PrP c and PrP
Sc mRNA is transcribed in the nucleus (A) and passed out to the cytoplasm, where it is translated by ribosomes at the endoplasmic reticulum (B). At this stage the N-terminal signal peptide is removed (C) to form the mature N-terminus (D), the sugars are added at N-linked glycosylation sites (E) and the C-terminal peptide is removed at the time that the GPI tail is added (F). The protein moves through the Golgi on its way to the surface (G) at which time the high mannose oligomers become trimmed and replaced with the mature sugar residues. PrP is released to the surface (H), and, through interaction with itself and/or other proteins, may form higher order structures (I). In uninfected cells PrP c is turned over by internalisation and lysosomal degradation (J). Whether endosomal recycling to the Golgi takes place is not known. For as yet unknown reasons, in infected cells PrP Sc is not degraded and accumulates in the cell (K). A proportion of PrP Sc is found to be partially digested, suggesting that it is exposed to proteolytic enzymes in passing through the lysosomes (24) .
however, leads to de-differentiation and a concomitant loss of scrapie infectivity associated with the cells and clearly they cannot be cloned. Scrapie infection does not appear to cause morphological or cytopathological changes in any of the cell systems described here.
Exactly which attributes of a cell line permit infection with TSE agents and the establishment of stable, persistent replication of the agent in vitro is still not known. The amount of infectious agent in cells is generally low, approximating at best to 1 LD50 per cell (102) . Infected mouse cells exhibited a stoichiometry between the number of infectious units and cells, indicating a reliance of the agent upon cell division for its replication (28) . Conversely, scrapie agent replication in PC 12 cells only proceeds in the differentiated, nominally quiescent, state.
Primary glial cells and glial-derived cell lines have been exposed to infectious scrapie agent in various studies (17, 82) but stable infection has not been reported, and not all neuroblastoma cell lines are suitable hosts for TSE passage in vitro (17, 82 (17, 23, 115) . Immuno fluorescence microscopy and cell-surface labelling with membrane-impermeable reagents have demonstrated that PrP c is located diffusely over the exterior of these cells (11, 115) . Radiolabelling pulse-chase experiments have shown that PrP c appears on the plasma membrane within 20 minutes and that it has a half-life on the surface of between 5 and 6 hours (11, 22) . PIPLC treatment of these cells removes about 50% of PrPC from the cell surface into the culture supernatant. Conversely, newly synthesised PrP
Sc cannot be labelled with membrane-impermeable label and is not solubilised by PIPLC. Pulse-chase labelling shows that its biosynthetic kinetics are very much slower than for PrP c , pulse-labelled protein only accumulating in the proteinase-K resistant fraction with a half-time of 15 hours. This is entirely consistent with the notion that PrP Sc is produced from precursor PrP Taraboulos and co-workers (114) have used scrapie-infected N2a clones to investigate the importance of N-glycosylation on PrP, in particular whether nonglycosylated PrP Sc is formed. They used two approaches to address this point, firstly the use of the glycosylation inhibitor tunicamycin and, secondly, the expression of a mutant gene in which both the N-linked glycosylation sites had been mutated to amino acid residues which could not be glycosylated by the cell. In both cases a proportion of the newly synthesised protein failed to reach the cell surface, being retained within the cell, but pulse labelled aglycosyl-PrP did enter the proteinase K-resistant PrP Sc fraction. The stability of aglycosyl-PrP c was shortened to 2 hours from 5 or 6 hours and the acquisition of proteinase K-resistance was shortened to a half-time of around 3 hours. Clearly, the addition of N-linked oligosaccharides is not the prime source of the physicochemical differences between PrP c and PrP Sc .
Regional expression of PrP
Generally the greatest concentration of the TSE infectious agent is associated with the brain, lesser amounts with the spleen and very low levels are associated with many other tissues. Several studies making use of Northern blot analysis (87, 98) or in situ hybridisation with probes specific for PrP mRNA (12, 68) have now shown the principal sites of PrP expression (Fig. 3) . Quantitatively, mRNA levels neither correlate directly with infectious titre nor alter during the course of the disease. Brain contains the greatest amounts of PrP mRNA, which is distributed in both neuronal and nonneuronal cells. It also contains the greatest infectious titre but heart and lung tissues, which contain almost as much mRNA as the brain, only ever contain trace levels of the infectious agent. Spleen contains only about 1% of the PrP mRNA that brain does, but is generally the organ with the second highest infectious titre. Still lower levels of mRNA are distributed in the intestine, liver and kidney. During embryonic development of the mouse, PrP mRNA can be detected at low levels by day 13, but expression is limited to specific regions of the brain. Much higher levels of PrP mRNA are found in other areas of the embryo, at all stages examined (6.5-16.5 days post conception) (80) . Levels of PrP mRNA continue to rise during brain maturation after birth (73) .
Given that the rates of transcription of mRNA, its degradation and levels of translation to protein may be under different constraints in different cell types, it is perhaps not surprising to find no quantitative correlation between infectivity and PrP mRNA. There is a better correlation though between the distribution of PrP 
Other mammalian PrPs
The description of PrP structure has largely been restricted to Syrian golden hamster PrP. DNA sequence and predicted amino acid sequence data are now available for the PrP of two other hamster species (77), mice (75, 118) , sheep (50), cow (51), rat (74) and humans (69) . The primary (amino acid) structure of these mature proteins (i.e. excluding the signal peptide and the C-terminal hydrophobic extension which is replaced by the GPI anchor) is conserved, the overall homology being in the order of 89% (Fig. 1) . Most of the differences are conservative substitutions in that the alternative amino acid residues would be expected to have little effect on overall structure. The higher order structure is unlikely to be very different from that discussed above for hamster PrP. What is evident, however, is that allelic variation occurs in these species and this leads to heterologous PrP isoforms.
THE PrP GENE
Isolation of the gene
Oesch et al. (87) purified PrP
Sc 27-30 from scrapie-infected hamster brains and sequenced the proximal part of the amino terminus. From the amino acid sequence they deduced all the possible combinations of nucleotide sequences that could theoretically code for the amino terminus of PrP Sc and synthesised a mixture of radiolabelled oligonucleotides based on these sequences. These were used as probes to identify clones containing PrP coding sequences. Messenger RNA (mRNA) was prepared from a pool of scrapie-infected hamster brains, copied into DNA (cDNA) by reverse transcriptase and cloned in a plasmid vector. Bacterial clones carrying a Plasmid with the putative PrP cDNA were identified by hybridisation with the labelled mixture of synthetic oligonucleotides. The capacity of the cDNA to code for PrP was confirmed by DNA sequence analysis which indicated that it contained the complete coding sequence together with 5' and 3' non-translated sequences.
PrP is encoded by a single-copy conserved host gene
Possession of a cDNA clone of PrP mRNA enabled questions about the origin of the PrP gene in hamster scrapie to be addressed. By using radiolabelled PrP cDNA as a hybridisation probe Oesch et al. (87) were unable to detect PrP coding sequences within enriched PrP Sc fractions, whereas they readily identified hybridising fragments in Southern blots of uninfected hamster genomic DNA (Fig. 4) . Thus it was shown that the PrP protein is a single-copy chromosomal gene and is not encoded by any putative genetic material which may form part of the infectious agent.
Detailed analysis of the chromosomal organisation of the hamster PrP gene shows that it has two exons. The 5' exon 1 is short and of apparently variable size, being preceded by a region which has some similarity to promoters for "housekeeping" genes. The 3' exon 2 is approximately 2 kilobase pairs (kb) long and contains the complete and uninterrupted open reading frame for the protein which is followed by over a kilobase of untranslated sequence. The two exons are separated by an intron of approximately 10 kb in length (4).
A similar overall structure to the PrP gene and high conservation of sequence is observed in mice (118), humans, (69, 96) Southern blot analysis using radiolabelled PrP cDNA to probe Cheviot sheep DNA digested with the restriction endonuclease EcoRl identifies two fragments containing PrP gene sequences. The 4.4 kb fragment is found in DNA isolated from sheep carrying the Sip pA allele whereas the 6.8 kb fragment is found in the DNA from sheep carrying the Sip sA allele. The DNA from heterozyogote sApA sheep has one copy of each fragment. mouse or hamster due to additional 3' untranslated nucleotides (50) . Within a species, individual alleles of the PrP gene may differ slightly in nucleotide sequence (see the section entitled "Allelic differences in the PrP gene") but the "within-species" allelic differences are small compared to the "between-species" differences.
As will be seen, the nucleotide differences between different alleles of the PrP gene within a species may be closely linked to, if not actually responsible for, much or all of the genetic differences in determining incubation period as defined by Sinc or Sip. Thus, specific amino acid residue polymorphisms in PrP can have dramatic effects on the behaviour of individual isolates of scrapie in hosts of different Sinc or Sip background. This also suggests that it is likely that the larger interspecies differences in PrP sequence would have major effects on the ability of a scrapie strain adapted to replicate in one species to infect and cause disease in another species. This can account for at least part of the so-called "species barrier", but the strain of agent is also important.
The "species barrier" for TSE transmission is a term which describes the fact that many field isolates of a TSE fail to transmit to another species or transmit with difficulty. If transmission is achieved, it is frequently associated with a prolonged incubation period which may take one or more passages in the new host species to equilibrate at a minimum incubation period.
The "species barrier" is also observed when experimental laboratory TSE strains are passaged between different species. If part of the "species barrier" is analogous to an extreme form of PrP gene allelism, it is open to experimental investigation through the use of transgenic animals. The first experimental models chosen to undertake such studies were mice carrying copies of the hamster PrP gene (TgHaPrP) and these were challenged with the Sc237 (equivalent to 263K) hamster-adapted or Chandler mouse-adapted isolates of scrapie (105) (Fig. 5) . Sc237 produces clinical signs of disease within 75 days in normal hamsters, whereas mice remain healthy for several hundred days. Conversely, the Chandler isolate produces disease within 145 days in Sinc s7/s7 mice whereas it takes in excess of 250 days to show signs of illness in hamsters. The response of transgenic mice to challenge with these scrapie isolates varied depending on the copy number of hamster PrP transgenes. Broadly, the higher the number of hamster PrP genes the more hamster-like became the response to challenge. Strain Tg(Ha-PrP)81 mice, which had a high copy number of hamster gene, developed clinical disease within 75 days of injecting Sc237 and had a significantly longer incubation period than normal control mice when challenged with the Chandler isolate.
Further characterisation of the infectious agents replicated in the brains of Tg(HaPrP) mouse lines following challenge with the hamster-and mouse-adapted scrapie strains showed, in very general terms, that if a hamster-adapted strain of agent is injected, a hamster-like strain is recovered, whereas if a mouse-adapted strain of agent is put in, a mouse-like strain is recovered (95) (Fig. 5) . Furthermore, using a hamster PrP-specific monoclonal antibody it was possible to show that the infectious agent which was replicated following infection with Sc237 was associated with hamster PrP Sc , suggesting that the incoming hamster agent selected an association with the endogenous hamster PrP in preference to mouse PrP. Whether this association is solely an interaction between conformationally altered hamster PrP Sc and hamster PrP c in the transgenic mouse, or whether it involves a species-specific interaction between a putative "genetic" molecule other than PrP and its homologous PrP c remains to be determined (see the chapter entitled "The molecular nature of the transmissible agent"). Nevertheless, these experiments provide compelling evidence that PrP is involved in the "species barrier".
Allelic differences in the PrP gene
The close association of PrP Sc with infectivity during purification and with the molecular pathology in diseased animals, together with the dramatic effect of the Sinc (Prn-i) or Sip genes on the course of the disease, led to the idea that incubation period genes and PrP genes may be one and the same. Linkage of restriction fragment length polymorphisms associated with the PrP gene with different alleles of Sinc (Prn-i) supported the notion that there are different alleles of the PrP gene (termed Prn-p) and that particular alleles of Prn-p may be linked to different Sinc (Prn-i) alleles (18, 61) . This proposition has been tested directly by sequencing clones of PrP genes prepared from genomic DNA isolated from mice or sheep of known Sinc (Prn-i) or Sip genotype, respectively. Comparison of the sequence of the PrP gene of a NZW mouse (Prn-ia or Sinc s7 genotype) with that from an I/Ln mouse (Prn-i b or differed at codons 108 and 189 (118) (Fig. 1) . Codon 108 encodes leucine in "short" incubation mouse strains but phenylalanine in "long" incubation period strains. The polymorphism at codon 189 changes a threonine codon in "short" incubation mice to a valine and, in so doing, deletes a recognition site for the restriction enzyme BstE11, enabling a survey of other inbred strains of mice of known Sinc (Prn-i) genotype. All 17 "short" incubation period mouse strains tested retained the BstEl1 site, whereas the three "long" incubation period mouse strains had lost it. Direct sequencing of the PrP genes of Sinc congenic mice (16) allele contained flanking sequences which could influence the Sinc (Prn-i) phenotype. Alternatively, the shortening of incubation may be due to increased levels of total PrP c , in a similar way to that observed for the transgenic mouse carrying hamster PrP genes (see the section entitled "PrP is encoded by a single-copy conserved host gene"). Finally, the challenge scrapie "strain" used in these experiments was the Chandler isolate, which may contain a mixture of strains (15, 33) . It is unlikely that the issue of congruency of Prn-p with Sinc (Prn-i) will be formally resolved until transgenic mice can be produced by the replacement of the endogenous PrP coding sequence with an "exogenous" PrP coding sequence through homologous recombination. Such an experimental model would avoid the indeterminate effects of variable integration sites, copy number and interactions between heterologous PrPs. The only other animal for which information is available about incubation period genes is the sheep. In this case there is the added bonus that it is also the animal in which scrapie occurs naturally, although much of the data relates to experimental scrapie (37) . Evidence of clear linkage between the different Sip alleles and .EcoRl and HindIII polymorphisms associated with the PrP gene was demonstrated for an experimental Cheviot flock (62) (Fig. 4) . Initial sequencing of PrP genes isolated from a library of Suffolk sheep DNA indicated a polymorphism at position 171 of the coding sequence, which resulted in an arginine to glutamine substitution (50) (Fig. 1) . Further studies, by DNA sequencing (52) Direct DNA sequencing of the coding region of different copies of the bovine PrP gene revealed a different type of polymorphism, not observed in sheep or mice. In addition to a polymorphic Hindll restriction endonuclease recognition site, different copies of the bovine gene can have either 5 or 6 copies of the 24 nucleotide sequence which encodes the octapeptide repeat (51) (see the section entitled "Structure of PrP") ( Fig. 1) . Five copies of the repeat would appear to be normal in other species, suggesting that the 6-mer form of the bovine gene is probably a mutant form. To date there is no firm genetic evidence for differential susceptibility of individual cows to BSE, so it is not possible to comment on the significance of the extra octapeptide repeat in BSE pathogenesis. Rare variant PrP genes involving additional copies of the octapeptide repeat have been found in humans (see the section entitled "Mutations in the human PrP gene associated with TSEs") (Fig. 1) .
Mutations in the human PrP gene associated with TSEs
DNA sequence analysis has shown that familial CJD and GSS can be linked with rare mutations in the coding sequence of the human PrP gene (49, 58, 92) . Furthermore, there is evidence that a common human PrP polymorphism at residue 129, which can be either valine (approximately 1/3) or methionine (approximately 2/3) in the normal Caucasian population, may be involved in the incidence of both iatrogenic and spontaneous CJD. Patients suffering from iatrogenic CJD were found to have a statistically significant over-representation of homozygosity of the Val 129 allele (31) and analysis of the genomes of patients with spontaneous CJD showed a significant over-representation of homozygosity at residue 129 although here there was no correlation between disease and either the Val 129 or Met 129 allele (89) . This has been interpreted to indicate that homogeneity of PrP molecules within a cell enhances the ability of the infectious agent to replicate and cause disease.
Subsequent studies have indicated that the higher than expected occurrence of CJD in humans homozygous at codon 129 are those with "classical short duration" CJD, and that those with "atypical long duration CJD" do not exhibit a similar excess of homozygosity (30, 41) .
One way of looking at the familial human PrP gene mutations is to consider that they might act as dominant "short" incubation period alleles that predispose individuals who carry them to the effects of human TSE agents at a higher incidence than do common alleles. Alternatively, proponents of the "protein-only" hypothesis for the nature of the agent (see the chapter entitled "The molecular nature of the transmissible agent") suggest that the mutant PrP proteins produced in these individuals are themselves able to produce disease in the absence of any exogenous agent and create de novo an infectious particle. Furthermore, this particle is capable of producing disease following subsequent transmission to a normal experimental animal. The onset, duration, pathology and clinical symptoms of disease vary considerably with these families, in contrast to the highly predictable nature of experimental scrapie. Such variability could be a natural consequence of a stochastic process (random exposure to a pre-existing agent, which itself may vary, or variable conversion of PrP c to a disease-producing self-replicating PrP Sc form) occurring in the different genetic backgrounds of individual family members.
Elegant experiments have been set up in transgenic mice to attempt to resolve this issue (59) . These transgenic mice, designated Tg(GSSPrP), carried extra copies of a mouse Prn-p a gene which had been manipulated to contain a leucine substitution at codon 101, which is equivalent to the human codon 102 mutation found in some GSS families (Fig. lb) . Individual transgenic lines had different numbers of additional mutant transgenes and expressed these mutant genes to varying degrees. Although not all lines of Tg(GSSPrP) mice developed spontaneous disease, individual mice of one of the lines, Tg(GSSPrP)174, which expressed PrP c at levels more than eight fold higher than control litter-mates, developed signs of ataxia, lethargy and rigidity at between 7 and 39 weeks of age. Histological examination revealed the presence of characteristic spongiform degeneration, although they lacked amyloid plaques which are common in GSS pathology and, significantly, they had either no or barely detectable amounts of PrP Sc .
It is perhaps not so surprising to find that expression of a mutant gene can have severe pathological consequences -it is, after all, the basis of many inherited genetic disorders. What is crucial to the debate on the nature of the TSE agent is whether these Tg(GSSPrP) mice, in the absence of any exogenously supplied TSE agent, can produce de novo within their tissues, infectious material which produces disease when injected into normal mice. To address this, Hsiao et al. (60) transmission to the transgenic mouse strains and normal hamsters with material from one individual brain, but transmission to only the transgenic mice with material from a brain of a different progeny Tg(GSSPrP) mouse. In neither case was there transmission to normal mice. Thus the properties of the transmitted disease in recipient animals differed significantly between inocula derived from brains originating from different individual Tg(GSS-PrP)174 mice. In scrapie terms this can be interpreted to suggest that individual Tg(GSS-PrP)174 mice generate de novo distinct strains of an infectious agent.
Experiments of this type provide key approaches to resolving the role of PrP in TSEs, but at this early stage much still needs to be resolved. The data so far confirm the central role of the PrP gene in TSEs, but the precise relationship between PrP Sc and the infectious agent remains unclear. The low level of penetrance of disease upon transmission to recipient normal animals is a problem and although rigorous steps were taken to exclude the possibility of low-level contamination from exogenous strains of TSE, this must remain a formal possibility until further experiments confirm the phenomenon and the newly emerging strains have been fully characterised.
THE MOLECULAR NATURE OF THE TRANSMISSIBLE AGENT
The models As a result of early biochemical work and the unusual properties of scrapie it was variously proposed that the infectious agent consisted of only protein (2, 53), polysaccharide (43) or fragments of membranes (85) . Since the late 1960s many data, particularly on the involvement of PrP, has been accumulated about TSEs, but the molecular nature of the causative agent still remains to be resolved. There are currently several general propositions on the nature of the agent which need to be considered. a) A virus-like particle, perhaps in filamentous form (32) . In this model at least one of the protein components of the virus must be encoded by the virus genome, in contrast to the virino model. b) An unusual "sub-virus" particle, termed a virino (37) which is composed of a non-coding nucleic acid genome which determines strain characteristics in tight association with a protective "structural" host-encoded protein. The infectious nature of such a particle may be dependent on the continued interaction between the nucleic acid and the protein coat, with infectivity being lost if the two become dissociated. c) A "naked" nucleic acid genome, similar to the viroids found in plants, which do not appear to code for any translated product, but which are more or less pathogenic as a result of interaction with undetermined cellular processes (38, 64) . d) A protein which is capable of stably adopting one of perhaps several structural or conformational states and which can replicate such an altered state in a nonmodified isoform of the same native protein. This notion has been developed by Prusiner and colleagues in the formulation of the "Prion Hypothesis" (91) when the concept of an infectious PrP was proposed, although as originally presented the possibility of additional non-PrP molecules was not ruled out. e) A non-obligatory association of nucleic acid and PrP. Weissman (117) has proposed the concept of a two component "holoprion", in which the PrP Sc component (the "apoprion") by itself is able to transmit SE disease, as proposed in the Prion Hypothesis, but that association with a variant nucleic acid component (the "coprion") confers a replicative advantage and stability to maintain the characteristics of a strain in a similar way to that proposed in the virino hypothesis.
Protein is required to maintain infectivity
Of the five models noted in the previous section only the viroid hypothesis does not require protein in any form. The possibility that the infectious agent is solely nucleic acid is not consistent with the sensitivity of scrapie infectivity to treatment with water-saturated phenol, high concentrations of SDS or high molarities of urea, all of which are routinely used in various nucleic acid extraction procedures and which do not inactivate nucleic acids (38) . The failure to show a clear peak of inactivation by exposure of crude or partially purified scrapie affected brain homogenates to UV light of 254 nm indicates that the agent is not naked nucleic acid, but does not exclude the possibility that nucleic acid is involved in some form of nucleoprotein complex (70) . The resistance of scrapie infectivity to inactivation by various nucleases also suggests that if a nucleic acid is involved in determining the infectivity of a scrapie agent, it must be well protected by some other structural molecule.
If it is accepted that the scrapie agent cannot be "pure" nucleic acid, it can be concluded that protein must form an essential part of the agent. This notion is further supported by the sensitivity of scrapie infectivity to a number of treatments which are known to denature (e.g. urea, phenol, SDS), chemically modify (e.g. diethyl pyrocarbonate, phenylmethylsulphonyl fluoride) and digest (proteinase K, trypsin and pronase) proteins (27, 71, 79, 91, 93, 94) .
The nature of the proteinaceous component(s)
Having established that scrapie infectivity is dependent upon some form of protein component, it is necessary to consider the nature of this protein and its origin. In essence the question is whether at least one of the proteins associated with infectivity is encoded by an independent agent-specific genome (virus hypothesis) or whether all of the proteins associated with infectivity are of host origin. At this point it is necessary to take into account the limitations in the sensitivity of the methods used to assay infectivity (72, 99, 109) or assess purity and chemical identity of fractions, making it very difficult to come to clear-cut conclusions.
The central question is whether it has been established beyond doubt that the hostencoded protein PrP is the essential and, perhaps, only protein component of the infectious agent (91) . Alternatively, is it merely a host-encoded protein which happens to be accumulated specifically and in a modified form as a result of the molecular pathology induced by scrapie infection and which, because of its extreme propensity to aggregate as PrP Sc , tends to trap the infectious agent during commonly used purification procedures (1, 81) ? The central involvement of PrP in the development of the disease is not in doubt, but deductions about its identity as the infectious agent must be examined closely. Many of the arguments centre around the details of purification procedures and the measurement of the recoveries of infectivity and specific proteins in the derivation of specific infectivity measurements (LD 50 /mg protein).
The purification procedure for the 263K strain of hamster scrapie used by digestion, controlled digestion with proteinase K and multiple centrifugations on sucrose gradients to yield a final fraction which is highly enriched for both PrP 27-30 and 263K infectivity. This fraction has a specific infectivity of between 10 Purification of PrP 27-30 by affinity chromatography, using antibodies against hamster PrP, provides an alternative method for selection for the PrP molecule based solely on antibody/antigen interactions and infectivity is still found to co-purify (48) . Thus, in the extraction procedures adopted in these experiments, PrP 27-30 and infectivity are found to be tightly associated, irrespective of whether purification is on the basis of enrichment for infectivity or for PrP. Furthermore, incubation of PrP 27-30 with low dilutions of rabbit anti-hamster PrP 27-30 polyclonal antiserum reduced titred infectivity by up to 1.6 logs, but the underlying mechanism for this is not understood (103) .
The relationship between purified PrP Sc and infectivity in the hamster 263K scrapie strain has also been investigated by Gajdusek and colleagues using different extraction procedures coupled with high performance liquid Chromatograph (HPLC) columns (103) , Polyacrylamide gels (PAGE) (12) or agarose isoelectric focusing (IEF) gels (25) to purify further PrP Sc . After solubilisation by boiling in 1% SDS for a short period, infectivity was surprisingly retained and found to elute with PrP Sc after HPLC and co-migrate with PrP Sc in PAGE. After IEF separation, the majority of infectivity remained in the loading trough along with PrP Sc and other proteins, but detectable amounts of infectivity migrated to alkaline positions in the gel where no PrP Sc could be found. It has been argued (108) that the first two of these observations remain inconclusive because micelles of SDS, originating in the sample buffer, could have eluted infectivity co-incidentally with PrP Sc from the HPLC column and that the conformation of a putative scrapie nucleoprotein complex might cause it to migrate faster than its size would otherwise predict, resulting in its incidental co-migration with the PrP Sc fraction.
If PrP 27-30 is itself the infectious agent, it is interesting to note that this molecule has had the N-terminal portion (containing the octapeptide repeats) removed during the proteinase K step in purification (Fig. lb) . This is surprising in view of the linkage between octarepeat mutations in humans and the incidence of familial CJD (see the section entitled "Mutations in the human PrP gene associated with TSEs"). Clearly any hypothetical infectious "imprint" in the PrP molecule cannot reside in this N-terminal region since it is not present in the infectious form of the protein. If mutations in the octapeptide repeat region have any role in initiating CJD infectivity, they must help to promote the irreversible structural change in a distant domain in such a way that the change is not dependent on the continued presence of the repeats.
Solubilisation of fractions enriched for infectivity with the detergent Sarcosyl at the high pH of 8.9 (81, 106, 107) suggests that a substantial portion of infectivity of a hamster-adapted strain of CJD can be separated from the majority of hamster PrP on both density (composition) and sedimentation velocity (mass and shape) criteria, indicating that infectivity is not necessarily an inherent property of the PrP Sc molecule. Furthermore, when fractions which are enriched for infectivity are disaggregated, they become exquisitely sensitive to the action of proteinase K, indicating that the disease-specific structural conformation which imparts differential proteinase K-resistance to the PrP molecule may not be a necessary element of the infectious agent under these conditions (81) .
Two other lines of evidence suggest that infectivity and PrP 27-30 may not be absolutely linked. The first comes from the relationship between increases in the amounts of PrP 27-30 and levels of infectivity during the course of an infection. While these largely parallel each other, in keeping with the proposed infectious nature of PrP, the rate of increase of infectivity in hamster scrapie is slightly higher than the rate of accumulation of . This slight in vivo "dissociation" of infectivity and PrP 27-30 has been experimentally manipulated by treatment of hamsters with amphotericin B, which prolongs the incubation period of intracerebrally inoculated animals (90) . In untreated animals 263K scrapie infectivity increased exponentially along with PrP 27-30, but in amphotericin B treated animals PrP 27-30 accumulation was severely inhibited, altering the ratio of infectivity to PrP 27-30 by at least 50-fold (121) . The second line of evidence is provided by the Tg(GSSPrP) mice which display spontaneous spongiform degeneration of the brain as a result of the expression of high levels of a mutant form of PrP protein (see the section entitled "Mutations in human PrP gene associated with TSEs"). From the point of view of the discussion here, it was significant that these mice had very little, if any, PrP 27-30 in extracts of their diseased brains and yet this material is reported to contain transmissible levels of an infectious agent. Through manipulation of the biological system it would appear that infectivity per se can be shown to be separate from the majority of the conformationally altered PrP protein.
To conclude this section, it is clear that the majority of evidence points to the fact that, following purification, infectivity is found in close association with PrP, indicating that PrP is most likely to be an integral part of the structure of the infectious agent. The evidence does not, however, exclude the possibility that this association could result from the combined effects of high concentrations of PrP accumulated as part of the molecular pathology of the disease and the ability of PrP to selfaggregate in the form of fibrils, trapping an infectious agent which is otherwise independent of the PrP molecule.
One potential way to resolve this ongoing debate would be to attempt to "transmit" scrapie with conformationally restructured PrP protein expressed in vitro from a cDNA clone. In this way it should be possible to ensure that the PrP molecule had never been in contact with any extraneous scrapie infectivity such that a positive result would be a clear-cut demonstration of the infectivity of the PrP clone. As is often the case, this experiment is not as simple as it might seem at first sight. A clone of mouse PrP cDNA was used to express glycosylated PrP polypeptides following transfection into mouse C127 cells in culture. Homogenates of the PrP-expressing cells were inoculated into the brains of susceptible mice, but these failed to develop signs of scrapie (21) . PrP protein expressed from hamster PrP cDNA cloned in a baculovirus vector also failed to produce scrapie after inoculation into hamsters, but the expressed protein did not have the properties of PrP Sc usually associated with infectivity (104) . This highlights the fundamental problem with this experimental approach. It is known that the normal isoform of PrP is not infectious, so "normal" PrP produced by recombinant DNA methods would not be expected to be infectious. It is only during scrapie infection that the conformational change is induced in PrP, and it is this altered state that is claimed to impart the property of infectivity. As there is no clue to the nature of the change that converts PrP c to PrP Sc , it is not possible to design procedures to introduce this change into recombinant PrP.
Is there a nucleic acid component to the infectious agent?
While it may not be possible to conclude with certainty that PrP Sc forms an essential component of the infectious particle, it should be possible to establish that nucleic acid is absent from the particle, thereby eliminating the virus, virino and holoprion hypotheses. In broad terms, the extreme resistance of infectivity to inactivation by chemical, physical and enzymatic treatments which would normally damage nucleic acids (6), coupled with the small estimated molecular size, have been interpreted to indicate that nucleic acid is not an integral part of the infectious agent (91) . However, as pointed out by Carp et al. (19) and others, the individual pieces of evidence are open to alternative explanations and it is not possible to exclude the possibility that a small nucleic acid genome of some kind is an essential component of the infectious agent.
Early experiments, which attempted to inactivate the scrapie agent with ionising radiation, suggested that, if there was any nucleic acid, it must be very small. Ionising radiation has subsequently been used to estimate the target size of the putative genome by comparison with the behaviour of viruses with genomes of known molecular weight. The size of the scrapie genome could be 0.75 x 10 6 Da if single stranded or about 1.6 x 10 6 Da if double stranded. These are equivalent to nucleic acids of about 2 kilobases or 2 kilobase pairs, respectively, which is within the range of the genomes of the smallest known viruses and would certainly be able to account for a nontranslated genome postulated by the virino hypothesis (100).
The enhanced inactivation of the scrapie agent by exposure to monochromatic UV light of 237 nm, compared to that achieved by UV light of 254 nm, is not normally considered to be characteristic of a nucleic acid, but rather of a lipid or protein. A reappraisal of the UV inactivation approach, again using known viruses or the activities of biological macromolecules as standards, has indicated that the inactivation profile for the scrapie agent is not inconsistent with a nucleoprotein composition, and that it is not possible to exclude the possibility of a nucleic acid component in tight association with a protein in the infectious particle (70) .
It is worth stressing that the effects of ionising radiation, UV light and chemical inactivation (e.g. psoralens) (79) have all relied on inactivation of infectivity, i.e. reduction of infectious titre, as the measure for the target molecule. A more informative approach would be to use these and other well characterised mutagens to introduce mutations in the scrapie agent which could be recognised as changes in the biological properties of strains. Thus if mutagens, which specifically target nucleic acids, were found to induce changes in strain type, this would be good evidence for an involvement of a nucleic acid genome in the infectious agent whereas "mutations" induced by protein modifying compounds would indicate a protein basis for infectivity.
The observed resistance of scrapie infectivity to inactivation by a variety of nucleases (routinely included in purification procedures) has been cited as evidence that a nucleic acid cannot be responsible for the infectious component of the agent. However, not too much weight should be given to this evidence since the packaging of nucleic acid genomes within a protein capsid or envelope in conventional viruses often renders them inaccessible to the actions of nucleases.
Direct attempts to identify nucleic acids in highly purified infectious fractions, either by direct visualisation on electrophoretic gels or by cloning, have met with mixed results. Meyer et al. (84) failed to detect any single size class of scrapie-specific nucleic acid, but found evidence of some short variable length molecules in silver stained Polyacrylamide electrophoretic gels after deproteinisation of the purified prion preparations. Purification of CJD infectivity from hamster brain homogenates by a different procedure is reported to yield infectious particles of virus-like size and density, indicating the presence of nucleic acid-protein complexes (106) . Treatment of similar fractions with ribo-and micrococcal nucleases did not result in significant losses of infectivity, but did produce an approximately 7,000-fold enrichment for nucleic acid (107) . Most of the protected nucleic acids migrated as short variable length molecules of between 50 and 500 nucleotides, and are probably equivalent to the fragments reported by Meyer et al. (84) . However, a minor smear of larger fragments (up to about 2 kb) was also identified. This is within the range of sizes predicted by the re-evaluation of the ionising radiation experiments (see above) and is consistent with the notion of a small virus-like genome.
Finally, Oesch et al. (88) reported attempts to clone scrapie-specific nucleic acids from highly purified infectious preparations under conditions that enabled the recovery of clones containing globin sequences that had been added in the form of globin mRNA at a ratio of 10 3 globin mRNA molecules per LD 50 unit of infectivity. All but four clones containing inserts of more than 50 bp contained globin-derived sequences. Of these four, only two hybridised to hamster repetitive sequences and the other two were found not to be related to hamster nucleic acids and thus of unknown origin. The design of the cloning strategy was such that circular nucleic acids and double stranded RNAs would probably not have been cloned which leaves open the possibility that the putative scrapie nucleic acid could be in one of these forms. Experiments of this kind also suffer from the possibility that, if the putative nucleic acid genome cannot be dissociated from the protein with which it is complexed, the deproteinisation step would probably result in the removal of the nucleic acid from the analysis.
CONCLUDING REMARKS
In the foregoing review the authors have attempted to present some of the data on selected molecular aspects of the TSEs and the unsatisfying position remains of not being able to resolve the nature of the causative agent. Despite this, there is now a much clearer understanding of the wide-ranging role that PrP plays in these diseases and the existence of many strains of scrapie-like agents. PrP c is a normal membrane glycoprotein which is expressed during embryonic development, in the mouse at least, and is widely distributed in different adult tissues. Yet nothing is known of its normal function, save through its homology with avian p65-21 which might indicate a synaptic function related in some way to nerve signal transmission.
Upon infection, a proportion of the PrP synthesised in the cell is induced to undergo a conformational change and, in so doing, it is abnormally accumulated in association with vesicles, which may be secondary lysosomes. It is probably the on-going accumulation of aggregated and apparently non-degradable PrP Sc which ultimately kills the neuron and gives rise to spongiform vesicles, but nothing is known of how the infection initiates and maintains this cellular dysfunction nor of the structural change induced in PrP c which blocks its normal catabolism. However, these processes are dramatically influenced by the precise primary structure of one or other or all of the Sinc and PrP genes and their proteins, such that in certain situations, for example the GSS transgenic mouse, the combination of mutant PrP and high levels of expression can trigger disease in the apparent absence of any exogenous initiating infection.
More normally, though, the onset of disease appears to be initiated by infection with a TSE agent. The detailed progression of disease is influenced not only by the genetic background of the host but also critically by the strain of agent. The increasing documentation of multiple strains of TSE agents clearly points to the existence of some form of independent genetic identity. The challenge is there for the proponents of the virino or virus hypotheses to isolate and prove the identity of the nucleic acid genome. An equally demanding challenge falls to the proponents of the Prion hypothesis to come forward with a testable structural model for the range of selfpropagating conformational changes necessary to account for the spectrum of biological strains of agent. And, of course, the proponents of the holoprion hypothesis need to face both of these challenges.
